These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7138091)

  • 1. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
    Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
    Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
    [No Abstract]   [Full Text] [Related]  

  • 2. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
    Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of hormonal profile in adjusting therapy for prostate cancer].
    Granov AM; Molchanov OE; Karelin MI
    Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum testosterone level in patients with advanced prostatic cancer during androgen suppressive treatment].
    Fosså SD; Høst H; Aakvaag A
    Tidsskr Nor Laegeforen; 1981 Oct; 101(28):1570-3. PubMed ID: 7339933
    [No Abstract]   [Full Text] [Related]  

  • 6. Orchiectomy.
    Alfthan O
    Scand J Urol Nephrol Suppl; 1980; 55():117-20. PubMed ID: 6259721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma prolactin in different age groups (author's transl)].
    Weiske WH; Frick J
    Padiatr Padol Suppl; 1977; (5):49-55. PubMed ID: 917576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prolactin and prostatic cancer. Modification of testosterone serum levels in estrogen-induced hyperprolactinemia by bromocriptine].
    Maganto E; Mayayo T; Mateos JA; Verdú F; Escudero Barrilero A
    Actas Urol Esp; 1983; 7(4):289-94. PubMed ID: 6624577
    [No Abstract]   [Full Text] [Related]  

  • 9. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
    Hsing AW; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate].
    Baranowska B; Jeske W; Szymanowski J; Piechna K
    J Urol (Paris); 1983; 89(8):601-5. PubMed ID: 6203986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Androgenic shock" during treatment of prostate gland cancer].
    Religa Z
    Pol Przegl Chir; 1969; 41(4):Suppl 4a:534+. PubMed ID: 4896406
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of estrogen-resistant forms of cancer of the prostate].
    Marinbakh EB; Ar'e VM
    Urol Nefrol (Mosk); 1974; 39(4):68-74. PubMed ID: 4606039
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cancer of the prostate: estrogen therapy].
    Mauriac L; Richaud P; Mage P; Thomas L; Lamarche P
    Bull Cancer; 1986; 73(1):23-30. PubMed ID: 3779120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
    Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
    J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone hanges in carcinoma of prostate.
    Straffon WG
    Br J Urol; 1970 Dec; 42(6):743. PubMed ID: 5491936
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.
    Taşar C; Akdaş A; Kirkali Z
    Int Urol Nephrol; 1986; 18(1):71-4. PubMed ID: 2424860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
    Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
    Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.